Table 2.

Intraoperative blood loss and survival in 1016 patients who underwent lobectomy for lung cancer

	Patient number	IBL (mL, mean ± SD)	p value	5-year survival (%)	p value
IBL
≤318 mL	509	176 ± 81		73.6
>318 mL	507	713 ± 504	<0.0001a	45.0	<0.0001b
Gender
Male	640	525 ± 510		49.8
Female	376	307 ± 269	<0.0001a	73.9	<0.0001b
Age
<69	553	431 ± 403		62.9
≥69	463	460 ± 499	0.7622a	53.1	0.0082b
Pathologic stage
IA	402	330 ± 322		81.7
IB	220	415 ± 434		62.6
IIA	92	499 ± 403		56.9
IIB	71	644 ± 609		24.5
IIIA	192	568 ± 517		31.8
IIIB	10	722 ± 613		20.0
IV	29	674 ± 680	<0.0001c	10.2	<0.0001b
IA–IIB	785	402 ± 408		67.7
IIIA–IV	231	588 ± 543	<0.0001a	28.8	<0.0001b
Histologic type
Ad	660	373 ± 354		63.6
Non-Ad	356	577 ± 564	<0.0001a	48.9	<0.0001b
Year of operation
1983–2002	555	588 ± 485		47.6
2003–2012	461	272 ± 328	<0.0001a	72.4	<0.0001b
Total	1016	445 ± 449		58.3

^a: Mann-Whitney U test, ^b: Log-rank test, ^c: Kruskal-Wallis test. Ad: adenocarcinoma; IBL: intraoperative blood loss; Non-Ad: non-adenocarcinoma; SD: standard deviation